Last updated: March 13, 2026
What is NDC 62559-0740?
NDC 62559-0740 is a prescription drug identified by the National Drug Code (NDC). According to available records, this number corresponds to Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Vosevi is a combination antiviral used to treat hepatitis C virus (HCV) infections.
Market Overview
Market Size and Demand
- Prevalence of HCV: An estimated 2.5 million Americans live with chronic HCV, with the majority in high-risk groups such as IV drug users and those born between 1945-1965.
- Treatment Penetration: HCV treatment uptake increased following the approval of directly acting antivirals (DAAs). Vosevi was approved by the FDA in 2017 for specific HCV genotypes.
- Market Competition: Vosevi faces competition from other DAA regimens, such as Epclusa (Gilead), Harvoni (Gilead), and Mavyret (MSD/Merck).
Key Market Drivers
- Increasing awareness and screening
- Advances in treatment protocols
- Patent exclusivity and regulatory approvals
Supply Chain Dynamics
- Major suppliers: Gilead Sciences, Merck, and AbbVie
- Distribution channels: Specialty pharmacies, hospitals, clinics
- Price elasticity influenced by approval status and insurance coverage
Price History and Current Pricing
Historical Pricing Trends
- Initial Launch Price (2017): approximately $78,000 for a 12-week course
- Current Approximate Retail Price: $63,000 to $70,000 per treatment course, depending on payer discounts and negotiations
- Role of PBMs: Price discounts and rebates heavily influence net prices
Price Comparison
| Drug |
Typical Course Cost |
Approved Indications |
Year of Approval |
| Vosevi (62559-0740) |
$63,000–$70,000 |
HCV genotypes 1-6, previous treatment failure |
2017 |
| Epclusa |
$74,760 |
All major genotypes, no previous treatment required |
2016 |
| Harvoni |
$94,500 |
Genotypes 1,4,5,6 |
2014 |
| Mavyret |
$26,400 |
All genotypes, shorter duration |
2017 |
Reimbursement Dynamics
- Medicaid and Medicare Part D cover most of the cost
- Negotiated rebates can reduce net prices by 20-50%
- Insurance restrictions often limit access to specific drugs based on treatment history
Future Price Projections
Influencing Factors
- Patent expiration: No expiration currently announced for Vosevi; future generics unlikely before 2032-2037, given typical patent life extensions.
- Competition: Introduction of biosimilars or generics could lower prices.
- Policy shifts: Increased healthcare cost containment measures may pressure net prices.
Forecast
| Year |
Estimated Treatment Course Price |
Explanation |
| 2023 |
$60,000–$68,000 |
Current stable pricing, minor rebates trends |
| 2025 |
$55,000–$65,000 |
Competition heats up, rebates expand |
| 2030 |
$45,000–$55,000 |
Potential entry of generics or biosimilars |
Assumptions
- Price drops driven by increased generic competition if patent expires
- Continued payer pressure to lower drug expenditure
- No significant new indications extending patent rights
Strategic Insights
- Companies should monitor patent filings and legal pathways for exclusivity extension
- Negotiation with payers will be critical for maintaining optimal pricing
- Early market entry of generics could reduce the price by 30-50% within a decade
Key Takeaways
- NDC 62559-0740 (Vosevi) commands a premium due to its efficacy but faces downward price pressure from competition and policy pressure.
- Current treatment course prices range from $63,000 to $70,000.
- Short-term projections suggest stable pricing, with long-term declines contingent on patent and market dynamics.
- Competitive landscape modifications are necessary to secure market share and optimize pricing strategies.
FAQs
1. What factors could significantly alter Vosevi's price projections?
Patent expiry, regulatory approval of generics, changes in reimbursement policies, and market competition.
2. How does Vosevi compare to other HCV treatments in price and efficacy?
It is priced higher than Mavyret but lower than Harvoni and Epclusa. Efficacy profiles are comparable across DAAs, with Vosevi favored after previous treatment failures.
3. What is the typical reimbursement process for Vosevi?
Insurance companies negotiate rebates, discounts, and formulary placement, impacting final patient out-of-pocket costs.
4. Are there opportunities for price reductions through bulk purchasing?
Yes, insurance plans and large healthcare systems often secure discounts for volume purchasing.
5. When might generics or biosimilars challenge Vosevi’s pricing?
If patent protections expire around 2032-2037, generic approval could reduce prices by approximately 50% within five years of market entry.
Citations
- FDA. (2017). Vosevi (sofosbuvir/velpatasvir/voxilaprevir) prescribing information. Retrieved from https://www.fda.gov
- IQVIA. (2022). National Prescription Data.
- Medicare.gov. (2022). Part D Prescription Drug Coverage.
- U.S. Department of Health & Human Services. (2022). Hepatitis C Information.
